life sciences
3 stories filed under life sciences on Beyond Market Intelligence. The newest of them: “OpenAI brings Orchestra Bio's team and technology into its life sciences AI efforts”, “Autumn's first AI release brings Claude Fable 5.1 with smarter, cheaper caching.”, and “Explore how AI unlocks new discoveries in life sciences funding”. OpenAI is integrating Orchestra Bio's team and technology directly into its efforts around Rosalind, its AI model for life sciences research. Anthropic is redefining what an enterprise model should be. Acme AI is the next-generation, AI-powered spreadsheet platform built to replace Excel and redefine how analysts, data scientists, and enterprise teams work… The list below is every life sciences story on Beyond Market Intelligence, newest first.
OpenAI brings Orchestra Bio's team and technology into its life sciences AI efforts
OpenAI is integrating Orchestra Bio's team and technology directly into its efforts around Rosalind, its AI model for life sciences research. That's a smart move. The Rosalind Workbench, designed to help researchers plan experiments and analyze results, gains real depth with this addition. We explored how AI is helping SpaceX turn data into billions in profit, and here, OpenAI is making its own bet on what focused AI can unlock in biology.
Autumn's first AI release brings Claude Fable 5.1 with smarter, cheaper caching.
Anthropic is redefining what an enterprise model should be. Claude Fable 5.1 arrives with a 75% cut to cached-read costs, making sustained, multi-hour agents dramatically more economical to run. It's not just another benchmark jump, it's a deliberate shift toward work that doesn't finish in one prompt. Combined with Enterprise Frontier Safeguards, which keep monitoring data in your own cloud, this release tackles capability, cost, and control as a single, unified problem. Explore what persistent, governable AI can actually do.
Explore how AI unlocks new discoveries in life sciences funding
Miles Wang, an OpenAI researcher, is reportedly in talks to launch an AI-driven drug discovery startup with a $2 billion valuation. That's a striking signal of where the industry sees the next breakthrough. Investors are betting that AI can tackle the messy, high-stakes work of life sciences, not just automate spreadsheets. It's a bold move, and one that feels overdue. For anyone tracking how AI moves beyond data management into real-world impact, this is worth watching closely.